KRAS+ Lung Cancer Responds to Targeted TherapyKRAS+ Lung Cancer Responds to Targeted Therapy
Dr. H. Jack West reports on a small but promising study that showed increased survival in KRAS mutated lung cancer using selumetinib and docetaxel. Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news
More News: Cancer | Cancer & Oncology | Docetaxel | Health | Hematology | Lung Cancer | Study | Taxotere